JP2011518819A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518819A5
JP2011518819A5 JP2011505593A JP2011505593A JP2011518819A5 JP 2011518819 A5 JP2011518819 A5 JP 2011518819A5 JP 2011505593 A JP2011505593 A JP 2011505593A JP 2011505593 A JP2011505593 A JP 2011505593A JP 2011518819 A5 JP2011518819 A5 JP 2011518819A5
Authority
JP
Japan
Prior art keywords
independently
nhr
alkyl
saturated aliphatic
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011505593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518819A (ja
Filing date
Publication date
Priority claimed from GBGB0807609.3A external-priority patent/GB0807609D0/en
Application filed filed Critical
Publication of JP2011518819A publication Critical patent/JP2011518819A/ja
Publication of JP2011518819A5 publication Critical patent/JP2011518819A5/ja
Withdrawn legal-status Critical Current

Links

JP2011505593A 2008-04-25 2009-04-27 アリール−キノリル化合物及びその使用 Withdrawn JP2011518819A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4790208P 2008-04-25 2008-04-25
US61/047,902 2008-04-25
GB0807609.3 2008-04-25
GBGB0807609.3A GB0807609D0 (en) 2008-04-25 2008-04-25 Therapeutic compounds and their use
PCT/GB2009/001077 WO2009130487A1 (en) 2008-04-25 2009-04-27 Aryl-quinolyl compounds and their use

Publications (2)

Publication Number Publication Date
JP2011518819A JP2011518819A (ja) 2011-06-30
JP2011518819A5 true JP2011518819A5 (cg-RX-API-DMAC7.html) 2012-04-26

Family

ID=39522596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505593A Withdrawn JP2011518819A (ja) 2008-04-25 2009-04-27 アリール−キノリル化合物及びその使用

Country Status (10)

Country Link
US (1) US8383816B2 (cg-RX-API-DMAC7.html)
EP (1) EP2285805B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011518819A (cg-RX-API-DMAC7.html)
CN (1) CN102066371A (cg-RX-API-DMAC7.html)
AU (1) AU2009239785A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0911525A2 (cg-RX-API-DMAC7.html)
CA (1) CA2721575A1 (cg-RX-API-DMAC7.html)
GB (1) GB0807609D0 (cg-RX-API-DMAC7.html)
WO (1) WO2009130487A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007395B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
DK2531502T3 (da) 2010-02-01 2014-05-19 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi
US8933228B2 (en) 2010-06-17 2015-01-13 Respivert, Ltd. Respiratory formulations and compounds for use therein
ES2542647T3 (es) * 2011-03-09 2015-08-07 Merck Patent Gmbh Derivados de pirido[2,3 b]pirazina y sus usos terapéuticos
WO2014206343A1 (en) * 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
EP3575305A1 (fr) 2018-05-31 2019-12-04 Biocidal Alternative Solutions Procédé de fabrication de composés comprenant un groupe fonctionnel oxazolopyridinones
JOP20180131B1 (ar) * 2018-12-24 2023-03-28 Univ Of Petra مركبات الكوينولون المستبدلة واستخدامها في علاج السرطان وطريقة تحضيرها
TWI812301B (zh) * 2021-06-24 2023-08-11 南韓商Lg化學股份有限公司 作為ron抑制劑之新穎尿素衍生物化合物
CN121818673B (zh) * 2026-03-13 2026-06-26 昆明医科大学 一种喹啉磺酰胺化合物的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US238568A (en) * 1881-03-08 Washing-machine
JPS5665863A (en) 1979-10-31 1981-06-03 Tokyo Organ Chem Ind Ltd Novel aniline derivative, its preparation and pesticide containing the same
JPS5738777A (en) 1980-08-19 1982-03-03 Sogo Yatsukou Kk 2-sufanilamidopyrathyn derivative
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
EP0783572B1 (en) * 1994-09-22 2005-04-27 Licentia Ltd. Promoter for the receptor tyrosine kinase, tie
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
CA2744096C (en) * 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
CN1252054C (zh) 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
RU2230553C2 (ru) 1997-09-26 2004-06-20 Центарис АГ Способ модулирования функции серин/треонин протеинкиназы соединением на основе азабензимидазола, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологических состояний в организме, соединение на основе азабензимидазола, способ его синтеза и фармацевтическая композиция
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
GB2356398A (en) 1999-11-18 2001-05-23 Lilly Dev Ct S A Preparation of arylsulfamides
US6610688B2 (en) 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
US7238813B2 (en) * 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
EP1456364B1 (en) 2001-12-21 2011-03-23 The Wellcome Trust Mutations in the b-raf gene
JP4335136B2 (ja) 2002-08-09 2009-09-30 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
US20090118261A1 (en) 2004-08-31 2009-05-07 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
WO2007067444A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP2013207B1 (en) 2006-04-26 2012-04-25 Cancer Research Technology Limited Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
WO2008044688A1 (en) 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
DK2531502T3 (da) 2010-02-01 2014-05-19 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi

Similar Documents

Publication Publication Date Title
BR112020014151A2 (pt) Compostos de benzamida
RU2008109914A (ru) Применение производных тиенопиридона в качестве активаторов амфк и фармацевтические композиции, которые их содержат
BR0110548A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, método de tratamento de distúrbios mediados pelo receptor de neuropeptìdio y5 em um animal de sangue quente, método de tratamento de distúrbios da alimentação em um animal de sangue quente, método para promover perda de peso em um animal de sangue quente, e, uso de um composto ou de um seu sal, prodroga ou solvato farmacêuticamente aceitável
CA3186919A1 (en) Low molecular weight protein degraders and their applications
JP2021152063A5 (cg-RX-API-DMAC7.html)
JP2010528035A5 (cg-RX-API-DMAC7.html)
JP2006504766A5 (cg-RX-API-DMAC7.html)
WO2017180769A1 (en) Small molecules for immunogenic treatment of cancer
CN105753905A (zh) 新的化合物以及用于治疗的方法
BR112012018415A2 (pt) composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto.
AU2008213576A1 (en) Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CA3148211A1 (en) Aryl sulfonamides as small molecule stat3 inhibitors
RU2017103148A (ru) Производные 2-амино-бензимидазола и их использование в качестве ингибиторов 5-липоксигеназы и/или простагландин е-синтазы
RU99127433A (ru) Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина
MX2007005857A (es) Inhibidores de cinasa.
WO2017195069A1 (en) Oxaborole esters and uses thereof
JP2007515476A5 (cg-RX-API-DMAC7.html)
ES2825798T3 (es) Moduladores de canales de Ca2+ activados por liberación de Ca2+ (CRAC) y usos farmacéuticos de los mismos
JP7734663B2 (ja) カスパーゼ6阻害剤およびその使用
KR101320810B1 (ko) 신경 재생 및/또는 보호제
RU2007112675A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ
JP2002534390A (ja) 癌治療におけるアデノシンアゴニスト類の使用
ES2587064T3 (es) Sales fumarato novedosas de un antagonista del receptor de histamina H3
CA3147111A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2021007303A1 (en) Nanoparticle formulation of bcl-2 inhibitor